New combo therapy aims to wipe out breast cancer before surgery

NCT ID NCT05525767

Recruiting now Disease control Sponsor: Hebei Medical University Fourth Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding bevacizumab to standard chemotherapy before surgery can improve outcomes for people with early or locally advanced HER2-negative breast cancer. About 75 participants will receive the drug combination, and researchers will measure how many achieve a complete response (no cancer left in the breast tissue). The trial is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bevacizumab (a drug that blocks blood vessel growth to tumors) combined with chemotherapy
What this could lead to: If successful, this could show that adding bevacizumab to standard chemo before surgery improves the chance of eliminating all cancer cells in the breast at the time of surgery.
What could go wrong: This is a single-arm, phase 4 study with only 75 participants, so results may not apply broadly. Bevacizumab can cause side effects like high blood pressure, bleeding, or slow wound healing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Her2-receptor negative breast cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

The Fourth Hospital of Hebei Medical University
RECRUITING

Shijiazhuang, Hebei, 050011, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.